Ireland - English - HPRA (Health Products Regulatory Authority)

ciba geigy plc - calcitonin -

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - calcitonin 0.5 mg/ml - solution for injection - 0.5 mg/ml - active: calcitonin 0.5 mg/ml

Egypt - English - EDA (Egyptian Drug Authority)

novartis pharma egypt - injection - 0.5 mg

Egypt - English - EDA (Egyptian Drug Authority)

novartis pharma-switzerland - injection - 0.25 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - calcitonin salmon, quantity: 100 iu/ml - injection, solution - excipient ingredients: sodium acetate; sodium chloride; glacial acetic acid; water for injections - - active paget's diseasein patients who do not respond to alternative treatments or for whom such treatments are not suitable,- hypercalcaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - calcitonin salmon, quantity: 50 iu/ml - injection, solution - excipient ingredients: water for injections; glacial acetic acid; sodium chloride; sodium acetate - - active paget's diseasein patients who do not respond to alternative treatments or for whom such treatments are not suitable,- hypercalcaemia.

United States - English - NLM (National Library of Medicine)

cipla usa inc. - cinacalcet hydrochloride (unii: 1k860wsg25) (cinacalcet - unii:uaz6v7728s) - cinacalcet 30 mg - cinacalcet hydrochloride tablets are indicated for the treatment of secondary hyperparathyroidism (hpt) in adult patients with chronic kidney disease (ckd) on dialysis [see clinical studies (14.1)]. limitations of use: cinacalcet hydrochloride tablets are not indicated for use in patients with ckd who are not on dialysis because of an increased risk of hypocalcemia [see warnings and precautions (5.1)]. cinacalcet tablets are indicated for the treatment of hypercalcemia in adult patients with parathyroid carcinoma [see clinical studies (14.2)] . cinacalcet hydrochloride tablets are indicated for the treatment of hypercalcemia in adult patients with primary hpt for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy. [see clinical studies (14.3)] . cinacalcet hydrochloride tablets treatment initiation is contraindicated if serum calcium is less than the lower limit of the normal range [see warnings and precautions (5.1)]. risk summary l

Israel - English - Ministry of Health

teva israel ltd - cinacalcet as hydrochloride - tablets - cinacalcet as hydrochloride 30 mg - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. cinacalcet teva may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.reduction of hypercalcaemia in patients with:• parathyroid carcinoma.• primary hpt for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.

Israel - English - Ministry of Health

teva israel ltd - cinacalcet as hydrochloride - tablets - cinacalcet as hydrochloride 60 mg - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. cinacalcet teva may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.reduction of hypercalcaemia in patients with:• parathyroid carcinoma.• primary hpt for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.

Israel - English - Ministry of Health

teva israel ltd - cinacalcet as hydrochloride - tablets - cinacalcet as hydrochloride 90 mg - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. cinacalcet teva may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.reduction of hypercalcaemia in patients with:• parathyroid carcinoma.• primary hpt for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.